The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 24900372 |
60 |
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. |
TBA |
| 12930155 |
20 |
Pyrazole derivatives as partial agonists for the nicotinic acid receptor. |
Leiden/Amsterdam Center For Drug Research |
| 22209457 |
47 |
SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. |
Merck Research Laboratory |
| 24900295 |
61 |
Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia |
TBA |
| 20724150 |
51 |
Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. |
F. Hoffmann-La Roche |
| 20184326 |
40 |
Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. |
Merck Research Laboratories |
| 19309152 |
81 |
Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. |
Merck Research Laboratories |
| 18665582 |
12 |
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. |
Arena Pharmaceuticals |
Search and Browse
